VEGFA and sarcoma: Circulating levels of VEGF-A are elevated on average ten-fold in sarcoma patients compared to controls [14], and inhibition of VEGF-A or its receptors can effectively suppress tumor angiogenesis in mouse models of sarcoma [7].